You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: February 14, 2025

CLINICAL TRIALS PROFILE FOR PENTAGASTRIN


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Pentagastrin

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00164788 ↗ A Comparison of Gastric pH Control With High Dose Intravenous or Oral Esomeprazole Terminated Chinese University of Hong Kong Phase 2 2004-07-01 The investigators hypothesize that high dose esomeprazole 80mg given as a bolus, followed by 8mg/h would render gastric pH near neutral and that pH control with esomeprazole given in such a high dose either intravenous or orally is identical.
NCT00284700 ↗ Is Helicobacter Pylori Infection a Cause or Treatment Failure of Iron Deficiency Anemia in Children in Bangladesh? Completed International Centre for Diarrhoeal Disease Research, Bangladesh N/A 1997-12-01 Helicobacter pylori is recognized as a major gastrointestinal pathogen in developing countries. This microorganism infects up to 60% of children less than five years in those countries and is strongly associated with chronic gastritis and peptic ulcer disease in children and adults. The progression of gastritis to atrophy often leads to decreased gastric acid output, which is a well-known risk factor for anemia. Gastric acid is essential for increasing the bioavailability and absorption of non-heme dietary iron, the most important source of iron in developing countries. Numerous reports suggest that iron malabsorption secondary to low gastric acid output is a problem in developing world countries. It has been further observed that iron deficiency anemia is resistant to iron therapy particularly in these countries. In a recently completed study we observed an association of anaemia with H. pylori infection. We hypothesize that the poor bioavailability of iron in these countries could be related to H. pylori -induced low gastric acid output and we propose to investigate the role of H. pylori infection as a cause of anemia and treatment failure of iron supplementation in Bangladesh. A prospective, randomized, double-blind, placebo-controlled field trial is proposed among four groups ( 65 each) of H. Pylori infected children of 2-5 years of age with iron deficiency anemia. The children will be assigned to one of the four therapies: antibiotics alone (for H. Pylori eradication), antibiotic plus iron therapy, iron therapy alone, or placebo. Hemoglobin concentration, serum ferritin concentration, and transferrin receptor will be measured before and at 1 and 3 month after the intervention. We also propose a complementary study in an additional 20 children with H. Pylori infection and iron deficiency anemia to assess iron absorption with application of double stable isotopes. The change in hematological parameters will also be compared among the groups before and after the therapy. The results of this study are expected to have implications in the prevention and treatment of iron deficiency anemia in developing countries.
NCT00626262 ↗ Open, Randomized, Two Way Crossover Study Comparing the Effect of Esomeprazole Adminstered Orally and iv Completed AstraZeneca Phase 4 2002-07-01 The purpose of this study is to examine the effects of Nexium at a dose of 20mg administered orally compared to intravenously on the maximum acid output in subjects with symptoms of Gastroesophageal reflux disease (GERD).
NCT00629564 ↗ An Open, Randomized, Two Way Crossover Study Comparing the Effect of 20mg Esomeprazole Administered Orally and Intravenously as a 15 Minute Infusion on Basal and Pentagastrin-Stimulated Acid Output in Subjects With Symptoms of Gastroesophageal Reflu Completed AstraZeneca Phase 4 2002-09-01 This study looks at the effect on basal and pentagastrin-stimulated acid output of 40 mg Esomeprazole (Nexium) administered orally and intravenously as a 15-minute infusion to people with symptoms of Gastroesophageal Reflux Disease (GERD)
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Pentagastrin

Condition Name

Condition Name for Pentagastrin
Intervention Trials
Hypergastrinaemia 3
GERD 2
Iron Deficiency Anemia 1
No Systemic Infection 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Pentagastrin
Intervention Trials
Gastroesophageal Reflux 3
Esophagitis, Peptic 2
Constipation 1
Gastrointestinal Hemorrhage 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Pentagastrin

Trials by Country

Trials by Country for Pentagastrin
Location Trials
United Kingdom 4
China 1
United States 1
Bangladesh 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Pentagastrin
Location Trials
Texas 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Pentagastrin

Clinical Trial Phase

Clinical Trial Phase for Pentagastrin
Clinical Trial Phase Trials
Phase 4 3
Phase 2/Phase 3 1
Phase 2 1
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Pentagastrin
Clinical Trial Phase Trials
Completed 9
Terminated 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Pentagastrin

Sponsor Name

Sponsor Name for Pentagastrin
Sponsor Trials
Trio Medicines Ltd. 4
AstraZeneca 3
James Black Foundation 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Pentagastrin
Sponsor Trials
Industry 8
Other 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Pentagastrin: Clinical Trials, Market Analysis, and Projections

Introduction to Pentagastrin

Pentagastrin, a synthetic pentapeptide, is widely used in medical diagnostics for its ability to stimulate gastric acid secretion and thyrocalcitonin (TCT) release. Here, we will delve into the clinical trials, market analysis, and future projections of this drug.

Clinical Use and Trials

Gastric Acid Secretion

Pentagastrin is commonly used to assess gastric acid secretion. Studies have shown that a dose of 6 μg/kg is sufficient for maximal gastric stimulation, with consistent results and minimal side effects. In a study involving 23 patients, the mean deviation in responses was 9.9%, indicating reliable and reproducible results[1].

Detection of Medullary Thyroid Carcinoma (MTC)

Pentagastrin is also utilized as a provocative test for the detection of MTC. It elicits a rapid and intense TCT secretory response, making it a valuable tool for diagnosing MTC, especially in its early subclinical stages. A comparison study between pentagastrin injection and calcium infusion showed that pentagastrin induced a more rapid and intense TCT response, highlighting its efficacy in this context[4].

Market Analysis

Global Market Size and Growth

The global pentagastrin market has shown significant growth over the years. As of 2022, the market value was reported to be in the millions of USD, with projections indicating it will continue to grow, reaching a higher value by 2029 at a CAGR of X.X%[2][5].

Market Segmentation

The pentagastrin market is segmented by product type, downstream industry, and region. Key regions include North America, Europe, Asia Pacific, Middle East & Africa, and Latin America. The market is also analyzed based on its concentration ratio and market maturity, providing a comprehensive view of the competitive landscape[2][5].

Competitive Landscape

Prominent players in the pentagastrin market, such as Acinopeptide Co, Ltd, are comprehensively analyzed in market reports. These analyses include sales data, growth rates, and global market shares, offering insights into the competitive situation and market performance of each player[2].

Market Projections

Future Trends

The pentagastrin market is expected to continue its upward trend, driven by increasing demand for diagnostic tools in gastroenterology and oncology. The forecast period from 2018 to 2029 indicates steady growth, with the market reaching a significant value by the end of the forecast period[2][5].

Regional Analysis

The market is distributed across various regions, with North America, Europe, and Asia Pacific being key contributors. Each region's production value and growth rate are analyzed, providing a detailed picture of the market's geographical distribution[5].

Side Effects and Safety Profile

Clinical trials have shown that pentagastrin is generally well-tolerated. In a study involving 150 patients, only 3 reported side effects, which were slight and of short duration, not affecting the study's outcome[1].

Key Takeaways

  • Clinical Use: Pentagastrin is effective in stimulating gastric acid secretion and detecting MTC.
  • Market Growth: The global pentagastrin market is projected to grow significantly by 2029.
  • Market Segmentation: The market is segmented by product type, downstream industry, and region.
  • Competitive Landscape: Key players like Acinopeptide Co, Ltd dominate the market.
  • Safety Profile: Pentagastrin is generally well-tolerated with minimal side effects.

FAQs

What is pentagastrin used for?

Pentagastrin is used to stimulate gastric acid secretion for diagnostic purposes and to detect medullary thyroid carcinoma (MTC) by eliciting a thyrocalcitonin (TCT) response.

What is the optimal dose of pentagastrin for gastric acid stimulation?

The optimal dose of pentagastrin for maximal gastric stimulation is 6 μg/kg, as higher doses do not increase peak acid output[1].

How does pentagastrin compare to calcium infusion in detecting MTC?

Pentagastrin elicits a more rapid and intense TCT secretory response compared to calcium infusion, making it a more effective diagnostic tool for MTC[4].

What is the projected growth of the global pentagastrin market?

The global pentagastrin market is expected to grow at a CAGR of X.X% from 2018 to 2029, reaching a significant value by the end of the forecast period[2][5].

Are there any significant side effects associated with pentagastrin?

Pentagastrin is generally well-tolerated, with only slight and short-duration side effects reported in a small number of patients[1].

Which regions are key contributors to the global pentagastrin market?

Key regions contributing to the global pentagastrin market include North America, Europe, and Asia Pacific[5].

Sources

  1. Pentagastrin as a Stimulant in Routine Clinical Testing of Gastric Acid Secretion - Karger.
  2. Global Pentagastrin Industry Market Competitive Analysis, Status and Forecast 2022-2029 - Maia Research.
  3. Quarterly Drug Pipeline: July 2024 - Prime Therapeutics.
  4. A Comparison of Pentagastrin Injection and Calcium Infusion as Clinical Stimulatory Tests for the Detection of Medullary Thyroid Carcinoma - Journal of Clinical Endocrinology and Metabolism.
  5. Global Pentagastrin Industry - Market Research Store - Market Research Store.

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.